Clinical trial · no report yet · Phase 3
NCT04214262
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
- NCT04214262 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8
- Interventions
- Atezolizumab; Biospecimen Collection; Computed Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy
- Arms
- Arm A (atezolizumab, SBRT) · Experimental
- Arm B (SBRT) · Active comparator
- Enrollment
- 417
- Primary outcomes
- Overall Survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Aug 13, 2020
- Primary completion
- Aug 24, 2024
- Results posted
- Yes
- Registry record
- NCT04214262 · updated Oct 6, 2026
Publications
linked from the registry- Daly ME, Simone CB 2nd, Redman MW, Hsieh MH, Hesketh PJ, Hu C, Monjazeb AM, Steuer CE, Ganti AK, Kashani R, Bauman JR, Feliciano JL, Moon J, Ku K, Le-Lindqwister N, Baschnagel AM, Maraboyina S, Sherwood GB, Almquist D, Higgins KA, Gray JE, Bradley JD, Kelly K. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet. 2026 Sep 6:S0140-6736(26)01655-7. doi: 10.1016/S0140-6736(26)01655-7. Online ahead of print. PubMed 42702214